SOLV · 10-Q · 2026Q2

Solventum Corp

Filed 2026-08-05 · Healthcare · View original filing on EDGAR

Ranked Events

• Operating Cash Flow TrendsImportance 69 · Surprise 64
  Cash and cash equivalents decreased by $475 million in the first six months of 2026, compared with a $268 million decrease in the first six months of 2025. Operating cash flow declined year over year primarily because…
• Property Investment IncreaseImportance 68 · Surprise 58
  Net property, plant and equipment increased 18.0% to $1,565 million at June 30, 2026 from $1,326 million at December 31, 2025. Gross property, plant and equipment rose to $3,455 million from $3,193 million over the…
• Market Demand TrendsImportance 58 · Surprise 42
  Second-quarter 2026 sales benefited from approximately $125 million of advanced customer orders placed ahead of Solventum’s July 2026 U.S. ERP deployment. Management expects third-quarter sales to be negatively…
• Interest Rate and Refinancing ExposureImportance 56 · Surprise 24
  Solventum had $5.0 billion of senior notes outstanding at June 30, 2026, with maturities ranging from 2027 through 2064 and fixed interest rates from 5.31% to 6.09%. The Company also had a $1.0 billion three-year…
• Operating Expense TrendsImportance 54 · Surprise 40
  SG&A increased to 42.0% of sales in the second quarter of 2026 from 35.7% in the prior-year quarter, and to 41.6% from 36.4% for the first six months. The increase was driven by accrued legal expenses and higher costs…
• Geographic Revenue CommentaryImportance 54 · Surprise 40
  United States sales were $1.313 billion in the second quarter of 2026, representing 59.4% of worldwide sales, and increased 10.4% on a reported basis. International sales represented 40.6% of worldwide sales and…
• Liquidity and Debt PositionImportance 54 · Surprise 14
  Total debt was $5,079 million at June 30, 2026, compared with $5,035 million at December 31, 2025. Long-term debt excluding current maturities was $4,573 million at June 30, 2026, down from $5,035 million at year-end…
• Revenue Performance and MixImportance 54 · Surprise 40
  Second-quarter 2026 net sales increased 2.2% year over year to $2.209 billion, with 9.5% organic growth offset by an 8.3% negative impact from divestitures and other items. Six-month net sales decreased 0.4% to $4.216…
• Income Tax Rate ChangesImportance 53 · Surprise 82
  The effective tax rate for the second quarter increased to 14.4% from 12.5% in the prior-year quarter, primarily because of an unfavorable geographic mix of earnings. The six-month effective tax rate was 15.0%,…
• Gross Margin DriversImportance 51 · Surprise 50
  Cost of product declined to 47.5% of sales in the second quarter of 2026 from 51.9% in the prior-year quarter, a 4.4 percentage-point improvement. For the first six months, cost of product decreased to 49.9% of sales…
• FX / Currency HeadwindsImportance 50 · Surprise 24
  Solventum operates through foreign subsidiaries and uses foreign-currency forward contracts and cross-currency swaps to manage exchange-rate exposure. At June 30, 2026, the Company had approximately $1.2 billion of…
• Trade Policy and TariffsImportance 47 · Surprise 60
  The U.S. Supreme Court ruled on February 20, 2026 that the International Emergency Economic Powers Act did not authorize presidential tariffs, and tariffs imposed under that statute are expected to be fully refunded.…
• Acquisition / Partnership / DivestitureImportance 47 · Surprise 60
  On August 5, 2026, Solventum announced its intention to pursue a separation of the Health Information Systems business as part of portfolio optimization. The company will evaluate multiple separation pathways intended…
• Liquidity and Cash PositionImportance 44 · Surprise 46
  Cash and cash equivalents declined to $403 million at June 30, 2026 from $878 million at December 31, 2025. Foreign subsidiaries held approximately $291 million of June 30 cash, while the United States held…
• Product Liability LawsuitImportance 40 · Surprise 42
  3M is a defendant in approximately 8,400 U.S. lawsuits and one Canadian putative class action alleging that the Bair Hugger patient warming system caused surgical-site infections. Solventum agreed under its Separation…
• Headcount / RestructuringImportance 37 · Surprise 42
  In November 2025, Solventum approved the four-year “Transform for the Future” global initiative to support its long-term growth strategy and compete in a changing healthcare environment. The program includes…
• Product Portfolio RationalizationImportance 34 · Surprise 42
  MedSurg growth was partially offset by Solventum’s SKU rationalization program. The rationalization had a larger impact on the Infection Prevention and Surgical Solutions business. The filing does not quantify the…
• Capital Return ProgramImportance 34 · Surprise 42
  Solventum repurchased 3.9 million common shares during the second quarter of 2026 and 4.8 million shares during the six months ended June 30, 2026. The repurchases were conducted through open-market transactions under…
• Supply Chain ConstraintsImportance 29 · Surprise 24
  Solventum purchases the majority of its materials and services as needed, without unconditional commitments, which provides procurement flexibility. In limited cases, the company uses take-or-pay and similar vendor…
• Products and TechnologyImportance 26 · Surprise 24
  MedSurg growth was driven by I.V. site management products, including Tegaderm CHG, and by negative pressure wound therapy in Advanced Wound Care. Dental Solutions growth came from restorative and prevention solutions…

Revenue by Product (in millions)

Revenue by Geography (in millions)